Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BEZ235+ MEK162 · 1 trial · 2 indications
A complete treatment cycle is defined as 28 days of daily continuois treatment with study drug combination
| Arm | Type | Description |
|---|---|---|
| BEZ235 + MEK162 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BEZ235 + MEK162 | DRUG | - |
Inclusion Criteria: * histologically/cytologically confirmed, advanced non resectable solid tumors * Measurable or non-measurable, but evaluable disease as determined by RECIST 1.0 Exclusion Criteria: * Patients with primary CNS tumor or CNS tumor involvement * Diabetes mellitus - Unacceptable oc...
BEZ235+MEK162 is an investigational combination of two small molecules being studied for the treatment of unspecified adult solid tumors, as defined by the specific protocol. It is being developed by Pfizer, Inc. for oncology indications. The combination is currently in clinical development, with a Phase 1 trial completed.
BEZ235+MEK162 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical research on this combination therapy for the treatment of solid tumors in adult patients.
BEZ235+MEK162 is in Phase 1 clinical development. A Phase 1 trial has been completed, which evaluated the safety, pharmacokinetics, and pharmacodynamics of the combination in patients with selected advanced solid tumors. The drug is investigational and has not been approved by regulatory authorities.
BEZ235+MEK162 has been studied in one clinical trial, registered as NCT01337765. This Phase 1 study, titled "Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients," has been completed. The trial enrolled 29 participants across the United States, Australia, Canada, France, and Spain.
The completed Phase 1 trial of BEZ235+MEK162 was not randomized and was not double-blinded. It was an uncontrolled study, meaning there was no control group receiving a placebo or standard treatment. The trial enrolled 29 patients with advanced solid tumors.
BEZ235+MEK162 is a combination of two small molecule drugs. BEZ235 is a dual inhibitor of PI3K and mTOR, while MEK162 is a MEK inhibitor. Together, they target multiple signaling pathways involved in tumor growth. The combination is being studied for its potential effect on advanced solid tumors.